Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
|Slideshows|September 30, 2022
In Case You Missed It: Psychiatric Times Psychedelics Supplement
Author(s)Psychiatric Times Editors
Vol. 39, Issue 9 covers the latest in psychedelics research and development in psychiatry.
Advertisement
Advertisement
Related to this article
Nearly half of US adults who drink and use cannabis combine them at once; cannabis use disorder drives the trend, signaling urgent screening needs.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Olanzapine LAI (Weltruza) Receives FDA Approval for Schizophrenia
2
Moving Away From Treatment-Resistant Depression and Toward Difficult-to-Treat Depression
3
Blinding, Ethics, and Safety Safeguards in Psychedelic Clinical Research
4
Should Postpartum Psychosis Be Included in the DSM?
5